Q2 FY2026 EarningsQ2 FY26 results missed consensus on the bottom line, with a GAAP net loss of $27.6M compared to the $25.5M expected. GAAP EPS of -$0.65 beat the mean consensus of -$0.73, primarily due to a higher-than-anticipated share count rather than operational outperformance. A significant increase in R&D spending to $22.1M reflects the acceleration of the ALTO-207 PACE program, while a successful $100M financing in July extended the cash runway through 2030, mitigating near-term liquidity concerns.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Alto Neuroscience(ANRO) the EBIT is -29.13 M (-55.92%), Miss estimate;the EPS is -0.65 (+0%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.03B55.92%
-0.03B40.75%
-0.00B15.17%
EPSExceed expectations
-0.65--
-0.734613.01%
+0.084613.01%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf